Researchers discover an abnormal protein that accumulates in the brains of patients affected with ALS and frontotemporal dementia. The findings have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases.
Transgenic mice carrying a gene variant found in one third of people with ALS have faster disease progression and die sooner than those with a standard genetic model of the disease, a new study reports.
Researchers have discovered a neurotoxin linked to a range of neurodegenerative diseases in Lake Winnipeg. The neurotoxin, BMAA, is found in high concentration in Cyanobacteria during periods of bloom.
With the help of AI, researchers are developing digital biomarkers that use speech data to identify ALS and frontotemporal dementia.
Increasing the activity of interneurons in later 5 of the primary motor cortex in mouse models of ALS effectively slowed the onset of the disease.
According to researchers, a drug that has been used for decades to help treat malaria can lower levels of a biomarker associated with ALS.
Researchers report they have identified a molecular defect in motor neurons which could help explain the mechanisms underlying ALS.
Findings from a new ALS study provide a novel therapeutic target for the disease.
Researchers report microglia is critical for neuronal survival in ALS.
While evidence suggests pathological proteins linked to the onset and progression of neurodegenerative disorders are capable of spreading from cell-to-cell within the brains of affected individuals, new research shows no evidence to support concerns that these abnormal disease proteins are “infectious” or transmitted from animals to humans or from one person to another.
A new collaborative study has helped researchers to uncover some of the earliest molecular events in ALS.
Researchers create neurons from the skin cells of ALS patients in order to "treat" a gene defect in a dish.